AR110504A1 - T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM - Google Patents
T-CELL RECEIVERS AND IMMUNE THERAPY USING THEMInfo
- Publication number
- AR110504A1 AR110504A1 ARP170103447A ARP170103447A AR110504A1 AR 110504 A1 AR110504 A1 AR 110504A1 AR P170103447 A ARP170103447 A AR P170103447A AR P170103447 A ARP170103447 A AR P170103447A AR 110504 A1 AR110504 A1 AR 110504A1
- Authority
- AR
- Argentina
- Prior art keywords
- taa
- antigen recognition
- tcr
- nucleic acids
- immune therapy
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title 1
- 108091008874 T cell receptors Proteins 0.000 abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La divulgación en particular provee moléculas basadas en el receptor de células T (TCR) que son selectivas y específicas para el TAA. El TCR, y los fragmentos de unión a TAA derivados de los mismos, son útiles para el diagnóstico, tratamiento y prevención de enfermedades cancerosas que expresan el TAA. Además se proveen ácidos nucleicos que codifican para las construcciones de reconocimiento de antígeno, vectores que comprenden estos ácidos nucleicos, células recombinantes que expresan las construcciones de reconocimiento de antígeno y composiciones farmacéuticas que comprenden los compuestos. Reivindicación 1: Una construcción de reconocimiento de antígeno caracterizada porque comprende por lo menos una región determinante de complementariedad (CDR) 3 que tiene por lo menos 50% de identidad de secuencia con una secuencia de aminoácidos que se selecciona de las SEQ ID Nº 3, 9, 15, 21, 27 y 33.The disclosure in particular provides molecules based on the T-cell receptor (TCR) that are selective and specific for TAA. The TCR, and the TAA binding fragments derived therefrom, are useful for the diagnosis, treatment and prevention of cancerous diseases that express the TAA. In addition, nucleic acids encoding antigen recognition constructs, vectors comprising these nucleic acids, recombinant cells expressing antigen recognition constructs and pharmaceutical compositions comprising the compounds are provided. Claim 1: An antigen recognition construct characterized in that it comprises at least one complementarity determining region (CDR) 3 that has at least 50% sequence identity with an amino acid sequence that is selected from SEQ ID No. 3, 9, 15, 21, 27 and 33.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662431580P | 2016-12-08 | 2016-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110504A1 true AR110504A1 (en) | 2019-04-03 |
Family
ID=66325035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103447A AR110504A1 (en) | 2016-12-08 | 2017-12-07 | T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR110504A1 (en) |
| EA (1) | EA201991139A1 (en) |
-
2017
- 2017-12-07 EA EA201991139A patent/EA201991139A1/en unknown
- 2017-12-07 AR ARP170103447A patent/AR110504A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201991139A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124997T1 (en) | NOVEL T-CELL RECEPTORS AND IMMUNOTHERAPY USING THEM | |
| PE20191648A1 (en) | NEW T-CELL RECEPTORS AND IMMUNE THERAPY THAT USE THEM | |
| MX395287B (en) | NEW T LYMPHOCYTE RECEPTORS AND IMMUNOTHERAPY BASED ON THEIR USE. | |
| CR20190276A (en) | NEW T-CELL RECEPTORS AND IMMUNE THERAPY THAT USES THEM | |
| PH12020550600A1 (en) | Novel engineered t cell receptors and immune therapy using the same | |
| PH12019502151A1 (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| CR20190594A (en) | NOVELTY T-CELL RECEPTORS, AND IMMUNOTHERAPY USING THE SAME | |
| WO2018172533A3 (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
| AR091069A1 (en) | PROTEINS OF UNION TO ANTIGEN DIRECTED AGAINST THE ST2 RECEIVER | |
| AR110504A1 (en) | T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM | |
| PE20211452A1 (en) | NEW GENETICALLY MODIFIED T-CELL RECEPTORS AND IMMUNE THERAPIES THAT USE THEM | |
| CY1124826T1 (en) | T-CELL RECEPTORS AND IMMUNOTHERAPY USING THEM | |
| EA202090712A1 (en) | NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE | |
| CO2019006926A2 (en) | New T-cell receptors and immune therapy that uses them | |
| AR110682A1 (en) | T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM | |
| EA201990488A1 (en) | NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION | |
| EA201992002A1 (en) | T-CELL RECEPTORS AND IMMUNE THERAPY OF PRAME-POSITIVE CANCER DISEASES WITH THEIR APPLICATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |